Adiponectin: an Indispensable Molecule in Rosiglitazone Cardioprotection Following Myocardial Infarction

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2009 Nov 27

PMID 19940263

Citations 43

Authors

Ling Tao

Yajing Wang

Erhe Gao

Hangxiang Zhang

Yuexing Yuan

Wayne B Lau

Lawrence Chan

Walter J Koch

Xin L Ma

Affiliations

Soon will be listed here.

Abstract

Rationale: Patients treated with peroxisome proliferator-activated receptor (PPAR)-gamma agonist manifest favorable metabolic profiles associated with increased plasma adiponectin (APN). However, whether increased APN production as a result of PPAR-gamma agonist treatment is an epiphenomenon or is causatively related to the cardioprotective actions of PPAR-gamma remains unknown.

Objective: To determine the role of APN in rosiglitazone (RSG) cardioprotection against ischemic heart injury.

Methods And Results: Adult male wild-type (WT) and APN knockdown/knockout (APN(+ or -) and APN(- or -)) mice were treated with vehicle or RSG (20 mg/kg per day), and subjected to coronary artery ligation 3 days after beginning treatment. In WT mice, RSG (7 days) significantly increased adipocyte APN expression, elevated plasma APN levels (2.6-fold), reduced infarct size (17% reduction), decreased apoptosis (0.23 + or - 0.02% versus 0.47 + or - 0.04% TUNEL-positive in remote nonischemic area), attenuated oxidative stress (48.5% reduction), and improved cardiac function (P<0.01). RSG-induced APN production and cardioprotection were significantly blunted (P<0.05 versus WT) in APN(+ or -), and completely lost in APN(- or -) (P>0.05 versus vehicle-treated APN(- or -) mice). Moreover, treatment with RSG for up to 14 days significantly improved the postischemic survival rate of WT mice (P<0.05 versus vehicle group) but not APN knockdown/knockout mice.

Conclusions: The cardioprotective effects of PPAR-gamma agonists are critically dependent on its APN stimulatory action, suggesting that under pathological conditions where APN expression is impaired (such as advanced type 2 diabetes), the harmful cardiovascular effects of PPAR-gamma agonists may outweigh its cardioprotective benefits.

Citing Articles

Adipokines and their potential impacts on susceptibility to myocardial ischemia/reperfusion injury in diabetes.

Han R, Huang H, Zhu J, Jin X, Wang Y, Xu Y Lipids Health Dis. 2024; 23(1):372.

PMID: 39538244 PMC: 11558907. DOI: 10.1186/s12944-024-02357-w.

mA reader YTHDF1 promotes cardiac fibrosis by enhancing AXL translation.

Wu H, Jiang W, Pang P, Si W, Kong X, Zhang X Front Med. 2024; 18(3):499-515.

PMID: 38806989 DOI: 10.1007/s11684-023-1052-4.

Hypoadiponectinemia-induced upregulation of microRNA449b downregulating Nrf-1 aggravates cardiac ischemia-reperfusion injury in diabetic mice.

Meng Z, Liang B, Wu Y, Liu C, Wang H, Du Y J Mol Cell Cardiol. 2023; 182:1-14.

PMID: 37437402 PMC: 10566306. DOI: 10.1016/j.yjmcc.2023.06.004.

Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.

Meng Z, Zhang Z, Zhao J, Liu C, Yao P, Zhang L Circulation. 2023; 147(15):1162-1179.

PMID: 36883479 PMC: 10085855. DOI: 10.1161/CIRCULATIONAHA.122.063073.

Activation of PPAR Protects Obese Mice from Acute Lung Injury by Inhibiting Endoplasmic Reticulum Stress and Promoting Mitochondrial Biogenesis.

Tang Y, Wei K, Liu L, Ma J, Wu S, Tang W PPAR Res. 2022; 2022:7888937.

PMID: 36213491 PMC: 9534695. DOI: 10.1155/2022/7888937.

References

Lipscombe L . Thiazolidinediones: do harms outweigh benefits?. CMAJ. 2008; 180(1):16-7. PMC: 2612067. DOI: 10.1503/cmaj.081713. View

Chinetti G, Fruchart J, Staels B . Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000; 49(10):497-505. DOI: 10.1007/s000110050622. View

Bendall J, Cave A, Heymes C, Gall N, Shah A . Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002; 105(3):293-6. DOI: 10.1161/hc0302.103712. View

Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens R, Kern P . Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab. 2008; 296(3):E480-9. PMC: 2660148. DOI: 10.1152/ajpendo.90892.2008. View

Marfella R, DAmico M, Di Filippo C, Piegari E, Nappo F, Esposito K . Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia. 2002; 45(8):1172-81. DOI: 10.1007/s00125-002-0882-x. View

Jiang G, Dallas-Yang Q, Li Z, Szalkowski D, Liu F, Shen X . Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes. 2002; 51(8):2412-9. DOI: 10.2337/diabetes.51.8.2412. View

Tao L, Gao E, Bryan N, Qu Y, Liu H, Hu A . Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A. 2004; 101(31):11471-6. PMC: 509224. DOI: 10.1073/pnas.0402941101. View

Heusch G, Boengler K, Schulz R . Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008; 118(19):1915-9. DOI: 10.1161/CIRCULATIONAHA.108.805242. View

Forrat R, Sebbag L, Wiernsperger N, Guidollet J, Renaud S, de Lorgeril M . Acute myocardial infarction in dogs with experimental diabetes. Cardiovasc Res. 1993; 27(11):1908-12. DOI: 10.1093/cvr/27.11.1908. View

10.

Li A, Brown K, Silvestre M, Willson T, Palinski W, Glass C . Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106(4):523-31. PMC: 380255. DOI: 10.1172/JCI10370. View

11.

Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K . Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003; 14(6):561-6. DOI: 10.1097/00041433-200312000-00003. View

12.

Abbate A, Biondi-Zoccai G, Baldi A . Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol. 2002; 193(2):145-53. DOI: 10.1002/jcp.10174. View

13.

Pischon T, Girman C, Hotamisligil G, Rifai N, Hu F, Rimm E . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14):1730-7. DOI: 10.1001/jama.291.14.1730. View

14.

Shibata R, Sato K, Pimentel D, Takemura Y, Kihara S, Ohashi K . Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005; 11(10):1096-103. PMC: 2828682. DOI: 10.1038/nm1295. View

15.

Berg A, Combs T, Scherer P . ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002; 13(2):84-9. DOI: 10.1016/s1043-2760(01)00524-0. View

16.

Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K . PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50(9):2094-9. DOI: 10.2337/diabetes.50.9.2094. View

17.

Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Soejima H, Hokamaki J . The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart. 2003; 89(6):667. PMC: 1767676. DOI: 10.1136/heart.89.6.667. View

18.

Sidhu J, Kaposzta Z, Markus H, Kaski J . Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004; 24(5):930-4. DOI: 10.1161/01.ATV.0000124890.40436.77. View

19.

Kadoglou N, Iliadis F, Angelopoulou N, Perrea D, Liapis C, Alevizos M . Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabet Med. 2008; 25(3):333-40. DOI: 10.1111/j.1464-5491.2007.02375.x. View

20.

Liu H, Tao L, Gao E, Lopez B, Christopher T, Willette R . Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004; 62(1):135-44. DOI: 10.1016/j.cardiores.2003.12.027. View